Loading…
Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients
BACKGROUND To evaluate the immunological responses of personalized peptide vaccination combined with low‐dose glucocorticoids for advanced hormone refractory prostate cancer (HRPC) patients (pts). METHODS Eleven pts with advanced HRPC were treated with the vaccination and low‐dose glucocorticoids; 6...
Saved in:
| Published in: | The Prostate 2008-12, Vol.68 (16), p.1753-1762 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3957-3015b2eecc668561885f5f8d0658735c4b3dd408494984cfff6480ad2e4c1a643 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3957-3015b2eecc668561885f5f8d0658735c4b3dd408494984cfff6480ad2e4c1a643 |
| container_end_page | 1762 |
| container_issue | 16 |
| container_start_page | 1753 |
| container_title | The Prostate |
| container_volume | 68 |
| creator | Naito, Masayasu Itoh, Kyogo Komatsu, Nobukazu Yamashita, Yuichi Shirakusa, Takafumi Yamada, Akira Moriya, Fukuko Ayatuka, Hitoshi Mohamed, Elnisr Rashed Matsuoka, Kei Noguchi, Masanori |
| description | BACKGROUND
To evaluate the immunological responses of personalized peptide vaccination combined with low‐dose glucocorticoids for advanced hormone refractory prostate cancer (HRPC) patients (pts).
METHODS
Eleven pts with advanced HRPC were treated with the vaccination and low‐dose glucocorticoids; 6 pts with 10 mg/day of prednisolone (PDL) followed by 1 mg/day of dexamethasone at the time of progression, 1 pt with PDL, and 4 pts with dexamethasone. Peptide‐specific cellular and humoral responses were employed to monitor pre‐ and post‐ (6th) vaccination samples.
RESULTS
The vaccination combined with glucocorticoids was well tolerated with no severe adverse effects. Increments of IgG responses were observed in 1 of 4 or 8 of 10 pts tested who received PDL or dexamethasone, respectively, increment of cytotoxic T lymphocyte activity was observed in 2 of 4 or 5 of 7 pts tested, respectively. Vaccination with PDL or dexamethasone resulted in a decline of PSA (at least 50%) in 1 of 7 or 6 of 10 pts with significantly longer median TTP in the dexamethasone group, respectively.
CONCLUSION
Vaccination combined with dexamethasone could be recommended for further clinical trials from both immunological and clinical points of view. Prostate © 2008 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/pros.20847 |
| format | article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_pros_20847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PROS20847</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3957-3015b2eecc668561885f5f8d0658735c4b3dd408494984cfff6480ad2e4c1a643</originalsourceid><addsrcrecordid>eNp9kEtvUzEQhS0EoqGw4Qcgb9gg3TK-fmaJCqRIVcsjwNLy9QMMuQ_ZTkn49fUloexYjWb0zZkzB6GnBM4IQPtySmM-a0ExeQ8tCCxlA8D4fbSAVkLDCJUn6FHOPwAqDu1DdEKUFBIYWaDda78zvS_fTR4Hj110eBgLzttpSj5nHPt-W-fdOOYSh2-42-PJp8qaTfztXW2mEp3HN8baOJgSxwGHMWHjbsxgZ6CaK6Z4bOc-4akyfij5MXoQzCb7J8d6ij6_fbM-v2gur1fvzl9dNpYuuWwoEN613lsrhOKCKMUDD8qB4EpSbllHnWP19yVbKmZDCIIpMK71zBIjGD1FLw66thrJyQc9pdibtNcE9Byfnh3qP_FV-NkBnrZd790_9JhXBZ4fAZOt2YRUn4r5jptVBCWzEDlwv-LG7_9zUr__eP3p7_HmsBNz8bu7HZN-aiGp5Prr1Uqv4MuV-rBe6zW9Bb-vmd0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Naito, Masayasu ; Itoh, Kyogo ; Komatsu, Nobukazu ; Yamashita, Yuichi ; Shirakusa, Takafumi ; Yamada, Akira ; Moriya, Fukuko ; Ayatuka, Hitoshi ; Mohamed, Elnisr Rashed ; Matsuoka, Kei ; Noguchi, Masanori</creator><creatorcontrib>Naito, Masayasu ; Itoh, Kyogo ; Komatsu, Nobukazu ; Yamashita, Yuichi ; Shirakusa, Takafumi ; Yamada, Akira ; Moriya, Fukuko ; Ayatuka, Hitoshi ; Mohamed, Elnisr Rashed ; Matsuoka, Kei ; Noguchi, Masanori</creatorcontrib><description>BACKGROUND
To evaluate the immunological responses of personalized peptide vaccination combined with low‐dose glucocorticoids for advanced hormone refractory prostate cancer (HRPC) patients (pts).
METHODS
Eleven pts with advanced HRPC were treated with the vaccination and low‐dose glucocorticoids; 6 pts with 10 mg/day of prednisolone (PDL) followed by 1 mg/day of dexamethasone at the time of progression, 1 pt with PDL, and 4 pts with dexamethasone. Peptide‐specific cellular and humoral responses were employed to monitor pre‐ and post‐ (6th) vaccination samples.
RESULTS
The vaccination combined with glucocorticoids was well tolerated with no severe adverse effects. Increments of IgG responses were observed in 1 of 4 or 8 of 10 pts tested who received PDL or dexamethasone, respectively, increment of cytotoxic T lymphocyte activity was observed in 2 of 4 or 5 of 7 pts tested, respectively. Vaccination with PDL or dexamethasone resulted in a decline of PSA (at least 50%) in 1 of 7 or 6 of 10 pts with significantly longer median TTP in the dexamethasone group, respectively.
CONCLUSION
Vaccination combined with dexamethasone could be recommended for further clinical trials from both immunological and clinical points of view. Prostate © 2008 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.20847</identifier><identifier>PMID: 18767041</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Aged ; Antibody Formation - drug effects ; Antibody Formation - immunology ; Antineoplastic Agents, Hormonal - adverse effects ; Antineoplastic Agents, Hormonal - pharmacology ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Cancer Vaccines - adverse effects ; Cancer Vaccines - pharmacology ; Cancer Vaccines - therapeutic use ; Combined Modality Therapy ; Dexamethasone - adverse effects ; Dexamethasone - pharmacology ; Dexamethasone - therapeutic use ; Dose-Response Relationship, Drug ; glucocorticoids ; Gynecology. Andrology. Obstetrics ; Humans ; immunotherapy ; Male ; Male genital diseases ; Medical sciences ; Nephrology. Urinary tract diseases ; peptide vaccine ; Prednisolone - adverse effects ; Prednisolone - pharmacology ; Prednisolone - therapeutic use ; prostate cancer ; Prostatic Neoplasms - immunology ; Prostatic Neoplasms - therapy ; Retrospective Studies ; Treatment Outcome ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2008-12, Vol.68 (16), p.1753-1762</ispartof><rights>Copyright © 2008 Wiley‐Liss, Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3957-3015b2eecc668561885f5f8d0658735c4b3dd408494984cfff6480ad2e4c1a643</citedby><cites>FETCH-LOGICAL-c3957-3015b2eecc668561885f5f8d0658735c4b3dd408494984cfff6480ad2e4c1a643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20846317$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18767041$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naito, Masayasu</creatorcontrib><creatorcontrib>Itoh, Kyogo</creatorcontrib><creatorcontrib>Komatsu, Nobukazu</creatorcontrib><creatorcontrib>Yamashita, Yuichi</creatorcontrib><creatorcontrib>Shirakusa, Takafumi</creatorcontrib><creatorcontrib>Yamada, Akira</creatorcontrib><creatorcontrib>Moriya, Fukuko</creatorcontrib><creatorcontrib>Ayatuka, Hitoshi</creatorcontrib><creatorcontrib>Mohamed, Elnisr Rashed</creatorcontrib><creatorcontrib>Matsuoka, Kei</creatorcontrib><creatorcontrib>Noguchi, Masanori</creatorcontrib><title>Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
To evaluate the immunological responses of personalized peptide vaccination combined with low‐dose glucocorticoids for advanced hormone refractory prostate cancer (HRPC) patients (pts).
METHODS
Eleven pts with advanced HRPC were treated with the vaccination and low‐dose glucocorticoids; 6 pts with 10 mg/day of prednisolone (PDL) followed by 1 mg/day of dexamethasone at the time of progression, 1 pt with PDL, and 4 pts with dexamethasone. Peptide‐specific cellular and humoral responses were employed to monitor pre‐ and post‐ (6th) vaccination samples.
RESULTS
The vaccination combined with glucocorticoids was well tolerated with no severe adverse effects. Increments of IgG responses were observed in 1 of 4 or 8 of 10 pts tested who received PDL or dexamethasone, respectively, increment of cytotoxic T lymphocyte activity was observed in 2 of 4 or 5 of 7 pts tested, respectively. Vaccination with PDL or dexamethasone resulted in a decline of PSA (at least 50%) in 1 of 7 or 6 of 10 pts with significantly longer median TTP in the dexamethasone group, respectively.
CONCLUSION
Vaccination combined with dexamethasone could be recommended for further clinical trials from both immunological and clinical points of view. Prostate © 2008 Wiley‐Liss, Inc.</description><subject>Aged</subject><subject>Antibody Formation - drug effects</subject><subject>Antibody Formation - immunology</subject><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Antineoplastic Agents, Hormonal - pharmacology</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - adverse effects</subject><subject>Cancer Vaccines - pharmacology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Dexamethasone - adverse effects</subject><subject>Dexamethasone - pharmacology</subject><subject>Dexamethasone - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>glucocorticoids</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>immunotherapy</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>peptide vaccine</subject><subject>Prednisolone - adverse effects</subject><subject>Prednisolone - pharmacology</subject><subject>Prednisolone - therapeutic use</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - immunology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp9kEtvUzEQhS0EoqGw4Qcgb9gg3TK-fmaJCqRIVcsjwNLy9QMMuQ_ZTkn49fUloexYjWb0zZkzB6GnBM4IQPtySmM-a0ExeQ8tCCxlA8D4fbSAVkLDCJUn6FHOPwAqDu1DdEKUFBIYWaDda78zvS_fTR4Hj110eBgLzttpSj5nHPt-W-fdOOYSh2-42-PJp8qaTfztXW2mEp3HN8baOJgSxwGHMWHjbsxgZ6CaK6Z4bOc-4akyfij5MXoQzCb7J8d6ij6_fbM-v2gur1fvzl9dNpYuuWwoEN613lsrhOKCKMUDD8qB4EpSbllHnWP19yVbKmZDCIIpMK71zBIjGD1FLw66thrJyQc9pdibtNcE9Byfnh3qP_FV-NkBnrZd790_9JhXBZ4fAZOt2YRUn4r5jptVBCWzEDlwv-LG7_9zUr__eP3p7_HmsBNz8bu7HZN-aiGp5Prr1Uqv4MuV-rBe6zW9Bb-vmd0</recordid><startdate>20081201</startdate><enddate>20081201</enddate><creator>Naito, Masayasu</creator><creator>Itoh, Kyogo</creator><creator>Komatsu, Nobukazu</creator><creator>Yamashita, Yuichi</creator><creator>Shirakusa, Takafumi</creator><creator>Yamada, Akira</creator><creator>Moriya, Fukuko</creator><creator>Ayatuka, Hitoshi</creator><creator>Mohamed, Elnisr Rashed</creator><creator>Matsuoka, Kei</creator><creator>Noguchi, Masanori</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20081201</creationdate><title>Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients</title><author>Naito, Masayasu ; Itoh, Kyogo ; Komatsu, Nobukazu ; Yamashita, Yuichi ; Shirakusa, Takafumi ; Yamada, Akira ; Moriya, Fukuko ; Ayatuka, Hitoshi ; Mohamed, Elnisr Rashed ; Matsuoka, Kei ; Noguchi, Masanori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3957-3015b2eecc668561885f5f8d0658735c4b3dd408494984cfff6480ad2e4c1a643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Antibody Formation - drug effects</topic><topic>Antibody Formation - immunology</topic><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Antineoplastic Agents, Hormonal - pharmacology</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - adverse effects</topic><topic>Cancer Vaccines - pharmacology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Dexamethasone - adverse effects</topic><topic>Dexamethasone - pharmacology</topic><topic>Dexamethasone - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>glucocorticoids</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>immunotherapy</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>peptide vaccine</topic><topic>Prednisolone - adverse effects</topic><topic>Prednisolone - pharmacology</topic><topic>Prednisolone - therapeutic use</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - immunology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naito, Masayasu</creatorcontrib><creatorcontrib>Itoh, Kyogo</creatorcontrib><creatorcontrib>Komatsu, Nobukazu</creatorcontrib><creatorcontrib>Yamashita, Yuichi</creatorcontrib><creatorcontrib>Shirakusa, Takafumi</creatorcontrib><creatorcontrib>Yamada, Akira</creatorcontrib><creatorcontrib>Moriya, Fukuko</creatorcontrib><creatorcontrib>Ayatuka, Hitoshi</creatorcontrib><creatorcontrib>Mohamed, Elnisr Rashed</creatorcontrib><creatorcontrib>Matsuoka, Kei</creatorcontrib><creatorcontrib>Noguchi, Masanori</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naito, Masayasu</au><au>Itoh, Kyogo</au><au>Komatsu, Nobukazu</au><au>Yamashita, Yuichi</au><au>Shirakusa, Takafumi</au><au>Yamada, Akira</au><au>Moriya, Fukuko</au><au>Ayatuka, Hitoshi</au><au>Mohamed, Elnisr Rashed</au><au>Matsuoka, Kei</au><au>Noguchi, Masanori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2008-12-01</date><risdate>2008</risdate><volume>68</volume><issue>16</issue><spage>1753</spage><epage>1762</epage><pages>1753-1762</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
To evaluate the immunological responses of personalized peptide vaccination combined with low‐dose glucocorticoids for advanced hormone refractory prostate cancer (HRPC) patients (pts).
METHODS
Eleven pts with advanced HRPC were treated with the vaccination and low‐dose glucocorticoids; 6 pts with 10 mg/day of prednisolone (PDL) followed by 1 mg/day of dexamethasone at the time of progression, 1 pt with PDL, and 4 pts with dexamethasone. Peptide‐specific cellular and humoral responses were employed to monitor pre‐ and post‐ (6th) vaccination samples.
RESULTS
The vaccination combined with glucocorticoids was well tolerated with no severe adverse effects. Increments of IgG responses were observed in 1 of 4 or 8 of 10 pts tested who received PDL or dexamethasone, respectively, increment of cytotoxic T lymphocyte activity was observed in 2 of 4 or 5 of 7 pts tested, respectively. Vaccination with PDL or dexamethasone resulted in a decline of PSA (at least 50%) in 1 of 7 or 6 of 10 pts with significantly longer median TTP in the dexamethasone group, respectively.
CONCLUSION
Vaccination combined with dexamethasone could be recommended for further clinical trials from both immunological and clinical points of view. Prostate © 2008 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>18767041</pmid><doi>10.1002/pros.20847</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2008-12, Vol.68 (16), p.1753-1762 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_pros_20847 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Aged Antibody Formation - drug effects Antibody Formation - immunology Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - pharmacology Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Cancer Vaccines - adverse effects Cancer Vaccines - pharmacology Cancer Vaccines - therapeutic use Combined Modality Therapy Dexamethasone - adverse effects Dexamethasone - pharmacology Dexamethasone - therapeutic use Dose-Response Relationship, Drug glucocorticoids Gynecology. Andrology. Obstetrics Humans immunotherapy Male Male genital diseases Medical sciences Nephrology. Urinary tract diseases peptide vaccine Prednisolone - adverse effects Prednisolone - pharmacology Prednisolone - therapeutic use prostate cancer Prostatic Neoplasms - immunology Prostatic Neoplasms - therapy Retrospective Studies Treatment Outcome Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A42%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dexamethasone%20did%20not%20suppress%20immune%20boosting%20by%20personalized%20peptide%20vaccination%20for%20advanced%20prostate%20cancer%20patients&rft.jtitle=The%20Prostate&rft.au=Naito,%20Masayasu&rft.date=2008-12-01&rft.volume=68&rft.issue=16&rft.spage=1753&rft.epage=1762&rft.pages=1753-1762&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.20847&rft_dat=%3Cwiley_cross%3EPROS20847%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3957-3015b2eecc668561885f5f8d0658735c4b3dd408494984cfff6480ad2e4c1a643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/18767041&rfr_iscdi=true |